April 26, 2016

Relmada Therapeutics Provides Additional Details Regarding Upcoming R&D Day

Event Scheduled for May 4, 2016 from 10:00 a.m. to 12:00 p.m. in New York City

NEW YORK, April 26, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will hold its first R&D Day on May 4, 2016, from 10:00 a.m. to 12:00 p.m.

The R&D Day will be held in New York, NY and hosted by members of Relmada's executive leadership team. Relmada will provide a corporate update and in-depth review of the Company's R&D programs. A question-and-answer session will follow the formal presentations.

Along with the Relmada team, presentations will be given by the following scientific advisors to the Company:

- Dr. Gavril Pasternak, Anne Burnett Tandy Chair in Neurology at Memorial Sloan-Kettering Cancer Center and a Laboratory Head in the Molecular Pharmacology and Chemistry Program within the Sloan-Kettering Institute.
- Dr. Robert H. Dworkin, Professor of Anesthesiology, Neurology, Oncology, and Psychiatry, Professor of Neurology in the Center for Human Experimental Therapeutics, and Director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry.

Space is limited and in-person attendance at the R&D Day is by invitation only. A live webcast of Relmada's R&D Day will be available through the Company's website at www.relmada.com. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of

high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Contact

Investor Contact:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 646-677-3857
mbecker@relmada.com

Media Contact:
Lynn Granito
Berry & Company Public Relations
Tel: 212-253-8881
lgranito@berrypr.com

Logo - https://photos.prnewswire.com/prnh/20150113/168770LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/relmada-therapeutics-provides-additional-details-regarding-upcoming-rd-day-300257302.html

SOURCE Relmada Therapeutics, Inc.